Advertisement
UK markets close in 5 hours 36 minutes

  • FTSE 100

    8,117.75
    +38.89 (+0.48%)
     

  • FTSE 250

    19,834.33
    +232.35 (+1.19%)
     

  • AIM

    755.61
    +2.49 (+0.33%)
     

  • GBP/EUR

    1.1657
    +0.0001 (+0.01%)
     

  • GBP/USD

    1.2516
    +0.0005 (+0.04%)
     

  • Bitcoin GBP

    51,460.88
    +423.66 (+0.83%)
     

  • CMC Crypto 200

    1,392.53
    -4.01 (-0.29%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    83.89
    +0.32 (+0.38%)
     

  • GOLD FUTURES

    2,360.40
    +17.90 (+0.76%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,049.99
    +132.71 (+0.74%)
     

  • CAC 40

    8,034.35
    +17.70 (+0.22%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

European shares edge up for fourth straight session

Reuters - UK Focus

(ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon - see cpurl://apps.cp./cms/?pageId=livemarkets)

LONDON, July 12 (Reuters) - European shares edged higher on Tuesday, boosted by a rise in Shire (Xetra: S7E.DE - news) after positive drug trial results, with Daimler (LSE: 0NXX.L - news) also gaining after its quarterly results.

The STOXX Europe 600 was up 0.3 percent, up for a fourth straight session. On Monday it closed at its highest level since Britain voted to leave the EU, after Theresa May won the race the succeed Prime Minister David Cameron much more quickly than expected, reducing political uncertainty.

Shire rose 4 percent after the U.S (Other OTC: UBGXF - news) . Food and Drug Administration approved its latest eye drops, allowing the company to bring to market its most important pipeline medicine.

Daimler was also a top gainer, up 3.8 percent after beating expectations with a solid second quarter (Reporting by Alistair Smout; Editing by Andrew Heavens)